0001325812-14-000026.txt : 20140304 0001325812-14-000026.hdr.sgml : 20140304 20140304204927 ACCESSION NUMBER: 0001325812-14-000026 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140228 FILED AS OF DATE: 20140304 DATE AS OF CHANGE: 20140304 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc. CENTRAL INDEX KEY: 0000873303 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 930797222 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 7 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 857-242-3700 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 7 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Sarepta Therapuetics, Inc. DATE OF NAME CHANGE: 20120712 FORMER COMPANY: FORMER CONFORMED NAME: AVI BIOPHARMA INC DATE OF NAME CHANGE: 19980930 FORMER COMPANY: FORMER CONFORMED NAME: ANTIVIRALS INC DATE OF NAME CHANGE: 19970123 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Christopher Nishan Garabedian CENTRAL INDEX KEY: 0001492604 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14895 FILM NUMBER: 14667155 MAIL ADDRESS: STREET 1: 333 RIVER STREET STREET 2: #303 CITY: HOBOKEN STATE: NJ ZIP: 07030 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2014-02-28 0 0000873303 Sarepta Therapeutics, Inc. SRPT 0001492604 Christopher Nishan Garabedian 215 FIRST STREET CAMBRIDGE MA 02142 1 1 0 0 President and CEO Common Stock 28078 D Incentive Stock Option (right to buy) 29.03 2014-02-28 4 A 0 3444 0 A 2024-02-28 Common Stock 3444 3444 D Non-Qualified Stock Option (right to buy) 29.03 2014-02-28 4 A 0 186556 0 A 2024-02-28 Common Stock 186556 186556 D Includes 800 shares acquired under the Sarepta Therapeutics, Inc. 2013 Employee Stock Purchase Plan on February 28, 2014. Reflects a transfer exempt under Rule 16a-12 since the date of the Reporting Persons last ownership report. This option is exercisable at the rate of 25% of the shares on the first anniversary of the date of grant and 1/48th of the total granted shares on each monthly anniversary thereafter, such that the option will be fully exercisable on the fourth anniversary of the date of grant. /s/ David Tyronne Howton for Christopher Garabedian 2014-03-04